These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 30661197

  • 1. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H, Tanaka Y, Sano S, Kameda H, Taniguchi A, Kashiwagi T, Kawaberi T, Kimura J, Morita A.
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [Abstract] [Full Text] [Related]

  • 2. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
    Karadag O, Dalkilic E, Ayan G, Kucuksahin O, Kasifoglu T, Yilmaz N, Koca SS, Yazisiz V, Erten PT, Sayarlioglu M, Terzioglu ME, Erten S, Kalyoncu U.
    Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
    [Abstract] [Full Text] [Related]

  • 3. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
    Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y.
    Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study.
    Morita A, Okuyama R, Katoh N, Tateishi C, Masuda K, Komori T, Ogawa E, Makino T, Nishida E, Nishimoto S, Muramoto K, Tsuruta D, Ihn H.
    Mod Rheumatol; 2020 Jan; 30(1):155-165. PubMed ID: 30836036
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 6. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L, Humphries B, Rutherford M, Taieb V, Willems D, Tillett W.
    Arthritis Res Ther; 2024 Feb 15; 26(1):50. PubMed ID: 38360699
    [Abstract] [Full Text] [Related]

  • 7. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B.
    J Rheumatol; 2010 Sep 15; 37(9):1898-906. PubMed ID: 20595284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.
    Arthritis Care Res (Hoboken); 2013 Oct 15; 65(10):1666-73. PubMed ID: 23666608
    [Abstract] [Full Text] [Related]

  • 10. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
    Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D.
    Rheumatology (Oxford); 2010 Apr 15; 49(4):812-9. PubMed ID: 20100797
    [Abstract] [Full Text] [Related]

  • 11. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Agarwal P, Yang F, Kollmeier AP, Hsia EC, Shiff NJ, Zhou B, Han C, Shawi M, Tillett W, Mease PJ.
    Adv Ther; 2022 Oct 15; 39(10):4613-4631. PubMed ID: 35947349
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P, Psaltis D, Georgiadis A, Katsifis G, Theodoridou A, Gazi S, Sidiropoulos P, Tektonidou MG, Bounas A, Kandyli A, Vounotrypidis P, Sakellariou GT, Vassilopoulos D, Huang Z, Petrikkou E, Boumpas D.
    Rheumatol Int; 2023 Oct 15; 43(10):1871-1883. PubMed ID: 37402886
    [Abstract] [Full Text] [Related]

  • 14. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.
    J Am Acad Dermatol; 2012 Feb 15; 66(2):e67-76. PubMed ID: 21616560
    [Abstract] [Full Text] [Related]

  • 15. Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.
    Kenar G, Yarkan H, Zengin B, Can G, Birlik M, Önen F.
    Rheumatol Int; 2018 Nov 15; 38(11):2069-2076. PubMed ID: 30194455
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, Takeuchi T.
    Mod Rheumatol; 2018 Jan 15; 28(1):39-47. PubMed ID: 28704126
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA, ACTIVE investigators.
    Ann Rheum Dis; 2018 May 15; 77(5):690-698. PubMed ID: 29343507
    [Abstract] [Full Text] [Related]

  • 20. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV, Loginova EY, Getiya TS, Nasonov EL.
    Ter Arkh; 2018 May 11; 90(5):22-29. PubMed ID: 30701886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.